BACKGROUND
After acute myocardial infarction (AMI), treatment with beta-blockers and angiotensin-converting enzyme inhibitors (ACEI) is widely recognized as crucial to reduce risk of a subsequent AMI. However, many patients fail to consistently remain on these treatments over time, and long-term adherence has not been well described.
OBJECTIVE
To examine the duration of treatment with beta-blockers and ACEI within the 24 months after an AMI.
DESIGN
A retrospective, observational study using medical and pharmacy claims from a large health plan operating in the Northeastern United States.
SUBJECTS
Enrollees with an inpatient claim for AMI who initiated beta-blocker (N = 499) or ACEI (N = 526) therapy.
MEASUREMENT
Time from initiation to discontinuation was measured with pharmacy refill records. Associations between therapy discontinuation and potential predictors were estimated using a Cox proportional hazards model.
RESULTS
ACEI discontinuation rates were high: 7% stopped within 1 month, 22% at 6 months, 32% at 1 year and 50% at 2 years. Overall discontinuation rates for beta-blockers were similar, but predictors of discontinuation differed for the two treatment types. For beta-blockers, the risk of discontinuation was highest among males and those from low-income neighborhoods; patients with comorbid hypertension and peripheral vascular disease were less likely to discontinue therapy. These factors were not associated with ACEI discontinuation.
CONCLUSION
Many patients initiating evidence-based secondary prevention therapies after an AMI fail to consistently remain on these treatments. Adherence is a priority area for development of better-quality measures and quality-improvement interventions. Barriers to beta-blocker adherence for low-income populations need particular attention.
Similar content being viewed by others
References
National Institutes of Health; National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2004 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: National Institutes of Health; 2004
Everly MJ, Heaton PC, Cluxton RJ, Jr. Beta-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother. 2004;38(2):286–93.
Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med. 2003;115(6):473–9.
Smith SC, Jr, Blair SN, Bonow RO, et al. AHA/ACC scientific statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001;104(13):1577–9.
Williams SC, Schmaltz SP, Morton DJ, Koss RG, Loeb JM. Quality of care in U.S. hospitals as reflected by standardized measures, 2002–2004. N Engl J Med. 2005;353(3):255–64.
Burwen DR, Galusha DH, Lewis JM, et al. National and state trends in quality of care for acute myocardial infarction between 1994–1995 and 1998–1999: the Medicare health care quality improvement program. Arch Intern Med. 2003;163(12):1430–9.
Butler J, Arbogast PG, BeLue R, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 2002;40(9):1589–95.
Mitra S, Findley K, Frohnapple D, Mehta JL. Trends in long-term management of survivors of acute myocardial infarction by cardiologists in a government university-affiliated teaching hospital. Clin Cardiol. 2002;25(1):16–8.
Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J. 2003;145(3):438–44.
Wei L, Flynn R, Murray GD, MacDonald TM. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment? Pharmacoepidemiol Drug Saf. 2004;13(11):761–6.
Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol. 2005;21(6):485–8.
Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165(10):1147–52.
Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004;117(2):73–81.
Gregoire JP, Moisan J, Guibert R, et al. Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol. 2002;55(7):728–35.
Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203–12.
Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148(1):99–104.
United State Census Bureau. Census 2000 Summary File 3 (SF3)—Sample Data. Available at http://factfinder.census.gov/servlet/DatasetMainPageServlet?_program=DEC&_lang=en.
Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute; 1995.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.
Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. Cardiovasc Res. 1997;34(1):248–53.
Kramer JM, Hammill B, Anstrom KJ, et al. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J. 2006;152(3):451–58.
LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004;164(2):203–9.
Goodman LS, Gilman A, Brunton LL, Lazo JS, Parker KL. The Pharmacological Basis of Therapeutics, 11th ed. New York, NY: McGraw-Hill; 2006.
Grymonpre R, Cheang M, Fraser M, Metge C, Sitar DS. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care. 2006;44(5):471–7.
National Committee on Quality Assurance. HEDIS 2005, vol 2: Technical Specifications. Washington, DC: National Committee on Quality Assurance; 2005.
Acknowledgements
This study was supported in part through Agency for Healthcare Research and Quality grants U18-HS016097 and R24 HS011825; a grant by Horizon Blue Cross Blue Shield of New Jersey; and an Academic Excellence Center grant funded by Rutgers, the State University of New Jersey.
Conflicts of Interest
John Bowblis owns stocks of Glaxosmithkline and Pfizer; and is currently doing consulting for Glaxosmithkline. Stephen Crystal owns stocks of Johnson and Johnson, Bristol Myers Squibb, Lilly, and Merck and received honorarium for a lecture from Johnson and Johnson. The other authors reported no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Akincigil, A., Bowblis, J.R., Levin, C. et al. Long-Term Adherence to Evidence Based Secondary Prevention Therapies after Acute Myocardial Infarction. J GEN INTERN MED 23, 115–121 (2008). https://doi.org/10.1007/s11606-007-0351-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11606-007-0351-9